PARM-1 Inhibitors
Chemical inhibitors of PARM-1 can exert their inhibitory effects through interference with signaling pathways crucial for its functional activity. Staurosporine, for instance, is a broad-spectrum protein kinase inhibitor that can impede the phosphorylation events on which PARM-1 depends for its role in signaling, leading to its functional inhibition. Similarly, rapamycin directly inhibits the mTOR pathway, which is essential for cellular growth and survival processes. Given that PARM-1 is implicated in such processes, rapamycin's action can result in the functional suppression of PARM-1. Other kinase inhibitors such as LY294002 and Wortmannin target the PI3K/Akt pathway, upstream of many growth and survival signals. Inhibition of PI3K can prevent the activation or stabilization of PARM-1, thus curtailing its activity.
Further down the signaling cascades, PD98059 and U0126 selectively inhibit MEK1/2 within the MAPK/ERK pathway, a route potentially involving PARM-1 in cell proliferation. By blocking this pathway, these inhibitors disrupt the signaling that may be necessary for PARM-1 function. SB203580 and SP600125 target the stress-responsive p38 MAPK and the JNK pathway, respectively. The inhibition of these MAPKs can lead to a decrease in PARM-1 activity if it is associated with stress response mechanisms. Kinase inhibitors such as Gefitinib and Erlotinib, which target the EGFR tyrosine kinase, can inhibit PARM-1 by disrupting EGFR-mediated signaling. Sorafenib and Sunitinib, as multi-targeted receptor tyrosine kinase inhibitors, can also inhibit PARM-1 by obstructing the signaling pathways that involve receptor tyrosine kinases, which might be essential for the functional activity of PARM-1.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. PARM-1, being implicated in signaling pathways, relies on phosphorylation events; staurosporine can inhibit these phosphorylation processes, thus functionally inhibiting PARM-1's role in signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR pathway. Since PARM-1 is involved in cellular growth processes that are regulated by the mTOR pathway, inhibition of this pathway by rapamycin can lead to a functional inhibition of PARM-1. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. PI3K is upstream of several growth and survival pathways in which PARM-1 may participate. Inhibition of PI3K can lead to functional inhibition of PARM-1 by preventing its activation or stabilization. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is involved in the MAPK/ERK pathway. PARM-1, associated with cell proliferation pathways, would be functionally inhibited by the disruption of the MAPK/ERK signaling cascade. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. By inhibiting p38 MAPK, this chemical can interfere with stress response pathways, potentially leading to a functional inhibition of PARM-1 if PARM-1 is involved in these pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, key enzymes in the MAPK/ERK pathway. By blocking this pathway, U0126 can functionally inhibit PARM-1 if its activity is dependent on MEK1/2-mediated signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor, like LY294002. It can functionally inhibit PARM-1 by blocking the PI3K/Akt pathway, which is involved in various cellular processes that may include PARM-1's function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which participates in the AP-1 pathway that influences cell proliferation and apoptosis. Inhibition of JNK could lead to functional inhibition of PARM-1 if it is part of this signaling pathway. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib inhibits the EGFR tyrosine kinase. If PARM-1 activity is tied to EGFR signaling, then the inhibition of EGFR by gefitinib could result in the functional inhibition of PARM-1. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is another EGFR tyrosine kinase inhibitor. Similar to gefitinib, erlotinib can functionally inhibit PARM-1 by disrupting EGFR-mediated signaling pathways in which PARM-1 might be involved. | ||||||